COLL
Price
$37.74
Change
+$0.58 (+1.56%)
Updated
Aug 15 closing price
Capitalization
1.17B
82 days until earnings call
PBH
Price
$64.99
Change
+$0.39 (+0.60%)
Updated
Aug 15 closing price
Capitalization
3.18B
75 days until earnings call
Interact to see
Advertisement

COLL vs PBH

Header iconCOLL vs PBH Comparison
Open Charts COLL vs PBHBanner chart's image
Collegium Pharmaceutical
Price$37.74
Change+$0.58 (+1.56%)
Volume$352.19K
Capitalization1.17B
Prestige Consumer Healthcare
Price$64.99
Change+$0.39 (+0.60%)
Volume$698.76K
Capitalization3.18B
COLL vs PBH Comparison Chart in %
Loading...
COLL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PBH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
COLL vs. PBH commentary
Aug 16, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is COLL is a Hold and PBH is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 16, 2025
Stock price -- (COLL: $37.16 vs. PBH: $64.60)
Brand notoriety: COLL and PBH are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: COLL: 119% vs. PBH: 142%
Market capitalization -- COLL: $1.17B vs. PBH: $3.18B
COLL [@Pharmaceuticals: Generic] is valued at $1.17B. PBH’s [@Pharmaceuticals: Generic] market capitalization is $3.18B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $67.83B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.72B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

COLL’s FA Score shows that 1 FA rating(s) are green whilePBH’s FA Score has 0 green FA rating(s).

  • COLL’s FA Score: 1 green, 4 red.
  • PBH’s FA Score: 0 green, 5 red.
According to our system of comparison, COLL is a better buy in the long-term than PBH.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

COLL’s TA Score shows that 6 TA indicator(s) are bullish while PBH’s TA Score has 4 bullish TA indicator(s).

  • COLL’s TA Score: 6 bullish, 4 bearish.
  • PBH’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, COLL is a better buy in the short-term than PBH.

Price Growth

COLL (@Pharmaceuticals: Generic) experienced а +12.81% price change this week, while PBH (@Pharmaceuticals: Generic) price change was -4.45% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +6.26%. For the same industry, the average monthly price growth was +68.76%, and the average quarterly price growth was +80.82%.

Reported Earning Dates

COLL is expected to report earnings on Nov 06, 2025.

PBH is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+6.26% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PBH($3.18B) has a higher market cap than COLL($1.17B). COLL has higher P/E ratio than PBH: COLL (35.06) vs PBH (15.16). COLL YTD gains are higher at: 29.703 vs. PBH (-17.275). PBH has higher annual earnings (EBITDA): 362M vs. COLL (333M). COLL has more cash in the bank: 198M vs. PBH (97.9M). COLL has less debt than PBH: COLL (844M) vs PBH (1.04B). PBH has higher revenues than COLL: PBH (1.14B) vs COLL (664M).
COLLPBHCOLL / PBH
Capitalization1.17B3.18B37%
EBITDA333M362M92%
Gain YTD29.703-17.275-172%
P/E Ratio35.0615.16231%
Revenue664M1.14B58%
Total Cash198M97.9M202%
Total Debt844M1.04B81%
FUNDAMENTALS RATINGS
COLL vs PBH: Fundamental Ratings
COLL
PBH
OUTLOOK RATING
1..100
1459
VALUATION
overvalued / fair valued / undervalued
1..100
69
Overvalued
83
Overvalued
PROFIT vs RISK RATING
1..100
3944
SMR RATING
1..100
4762
PRICE GROWTH RATING
1..100
4285
P/E GROWTH RATING
1..100
663
SEASONALITY SCORE
1..100
5027

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

COLL's Valuation (69) in the Pharmaceuticals Other industry is in the same range as PBH (83). This means that COLL’s stock grew similarly to PBH’s over the last 12 months.

COLL's Profit vs Risk Rating (39) in the Pharmaceuticals Other industry is in the same range as PBH (44). This means that COLL’s stock grew similarly to PBH’s over the last 12 months.

COLL's SMR Rating (47) in the Pharmaceuticals Other industry is in the same range as PBH (62). This means that COLL’s stock grew similarly to PBH’s over the last 12 months.

COLL's Price Growth Rating (42) in the Pharmaceuticals Other industry is somewhat better than the same rating for PBH (85). This means that COLL’s stock grew somewhat faster than PBH’s over the last 12 months.

COLL's P/E Growth Rating (6) in the Pharmaceuticals Other industry is somewhat better than the same rating for PBH (63). This means that COLL’s stock grew somewhat faster than PBH’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
COLLPBH
RSI
ODDS (%)
Bearish Trend 3 days ago
69%
Bullish Trend 3 days ago
65%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
70%
Bullish Trend 3 days ago
57%
Momentum
ODDS (%)
Bullish Trend 3 days ago
72%
Bearish Trend 3 days ago
52%
MACD
ODDS (%)
Bullish Trend 3 days ago
76%
Bearish Trend 3 days ago
63%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
70%
Bearish Trend 3 days ago
54%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
71%
Bearish Trend 3 days ago
44%
Advances
ODDS (%)
Bullish Trend 6 days ago
72%
Bullish Trend 4 days ago
57%
Declines
ODDS (%)
Bearish Trend 3 days ago
63%
Bearish Trend 6 days ago
52%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
65%
Bullish Trend 3 days ago
69%
Aroon
ODDS (%)
Bullish Trend 3 days ago
80%
Bearish Trend 3 days ago
36%
View a ticker or compare two or three
Interact to see
Advertisement
COLL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PBH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
WBAIX17.11-0.03
-0.18%
Weitz Conservative Allocation-Instl Cl
JVAQX39.78-0.07
-0.18%
JPMorgan Value Advantage R4
NWAPX36.44-0.07
-0.19%
Nationwide BNY Mellon Dyn US Eq Inc Egl
LAVQX15.86-0.06
-0.38%
Lord Abbett Fundamental Equity R2
GCEEX9.66-0.09
-0.92%
Goldman Sachs Clean Energy Income R6

COLL and

Correlation & Price change

A.I.dvisor indicates that over the last year, COLL has been loosely correlated with AMPH. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if COLL jumps, then AMPH could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To COLL
1D Price
Change %
COLL100%
-1.85%
AMPH - COLL
43%
Loosely correlated
-0.89%
AMRX - COLL
38%
Loosely correlated
-0.11%
ALKS - COLL
37%
Loosely correlated
-1.29%
VTRS - COLL
36%
Loosely correlated
+2.69%
PAHC - COLL
36%
Loosely correlated
-1.26%
More

PBH and

Correlation & Price change

A.I.dvisor indicates that over the last year, PBH has been loosely correlated with PAHC. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if PBH jumps, then PAHC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PBH
1D Price
Change %
PBH100%
-2.75%
PAHC - PBH
40%
Loosely correlated
-1.26%
PRGO - PBH
30%
Poorly correlated
-2.66%
AMPH - PBH
27%
Poorly correlated
-0.89%
APNHF - PBH
26%
Poorly correlated
N/A
COLL - PBH
26%
Poorly correlated
-1.85%
More